Elan Moving Alzheimer’s Candidate To Phase II Under Pact With Transition Therapeutics
Initial terms of the partnership include an unusual 70/30 split on development costs and eventual profits.
Initial terms of the partnership include an unusual 70/30 split on development costs and eventual profits.